



Areacor Therapeutics plc
(“Areacor”, the “Company” or the “Group”)

ARECOR ANNOUNCES LAUNCH OF OGLUO® IN THE NETHERLANDS

- ***Launch builds on continued pan-European commercial roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK***

Cambridge, UK, 29 February 2024: Areacor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, notes the announcement today from subsidiary company, Tetris Pharma Ltd, that Ogluo® (glucagon prefilled autoinjector pen) has been launched in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.

Ogluo® has been launched in the Netherlands by Goodlife, under the previously announced, existing commercialisation agreement between Tetris Pharma Ltd and Goodlife, which has established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.

See full Tetris Pharma announcement below:

Ogluo® launches in the Netherlands

Availability of glucagon prefilled autoinjector pen in first BeNeLux country, in partnership with Goodlife, further expands reach of Ogluo® across Europe

Continued momentum in pan European roll-out following earlier launches in Denmark, Norway, Austria, Germany and the UK

29 February 2024 - Tetris Pharma Ltd (“Tetris Pharma” or “the Company”), a subsidiary of biopharmaceutical company, Areacor Therapeutics plc (AIM: AREC), today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in the Netherlands as a treatment for severe hypoglycaemia in adults, adolescents, and children aged two years and over living with diabetes mellitus.

The launch is part of an existing exclusive commercialisation agreement between Tetris Pharma Ltd and Goodlife, announced in September 2023, which established Goodlife as the sole partner for the import, marketing and distribution of the product in the BeNeLux region.



Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an auto-injector for patients within the licenced indication living with diabetes suffering from severe hypoglycaemia. Today's launch builds on the continued roll-out of Ogluo® across key European markets, including, Denmark, Norway, Austria, Germany and the UK, as part of Tetris Pharma's pan-European commercialisation programme.

Dr. Helen Parris, Senior Vice President, Commercial and General Manager of Tetris Pharma, commented:

"The launch of Ogluo® in the Netherlands presents a significant milestone for Tetris Pharma, strengthening the commercial reach and pan-European presence of this important product and giving patients living with diabetes who may experience severe hypoglycaemia, a treatment option to tackle those events. Goodlife's leading know-how and expertise of regional market dynamics make them an ideal partner to support with the roll-out of Ogluo® in the BeNeLux region. We look forward to continuing to expand our reach within Europe to bring this treatment option to people living with diabetes."

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo®, a ready-to-use glucagon for emergency use to treat hypoglycaemia. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance. For further information, please visit www.tetrispharma.com.

Goodlife is a privately owned pharmaceutical company with a focus on The Netherlands, Belgium and Luxembourg. Goodlife believes that every patient deserves excellent care that matches their individual needs, even if those needs deviate from the norm. With this in mind, we strive for customization every day, by providing unique medicines, medical devices, dietary supplements and supportive tools for individual patients in the BeNeLux. For more information, please visit www.goodlifepharma.com.

-ENDS-



For more information, please contact:

Areacor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Panmure Gordon (UK) Limited (NOMAD and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

WG Partners LLP (Financial Advisor)

Nigel Barnes, Satheesh Nadarajah

David Wilson, Claes Spang

Tel: +44 (0)203 705 9321

ICR Consilium

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Areacor

Areacor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com